Get to know our clinical trials
Directional stimulation of the subthalamic nucleus and impulse control disorder in Parkinson's disease.
IN PARKINSON'S DISEASE, THE ADMINISTRATION OF LEVODOPA AND DOPAMINERGIC AGONIST DRUGS IMPROVES MOTOR MANIFESTATIONS. HOWEVER, CHRONIC USE OF THESE DRUGS CAN CAUSE SIDE EFFECTS SUCH AS IMPULSE CONTROL DISORDER, WHICH IS ONE OF THE MOST FREQUENT AND PROBLEMATIC. IN THIS STUDY IN PATIENTS WITH PARKINSON'S DISEASE AND THIS COMPLICATION WE WILL ASSESS WHETHER THE IMPLANTATION OF AN ELECTRODE IN THE BRAIN THAT STIMULATES SELECTIVELY COULD ALLOW A MOTOR IMPROVEMENT THAN THE TRADITIONAL FORM OF STIMULATION AND A GREATER REDUCTION OF THE DOSE OF DOPAMINERGIC DRUGS IMPROVING THE IMPULSE CONTROL DISORDER BUT MAINTAINING THE MOTOR BENEFIT. WE WILL ALSO STUDY IF WITH THIS DIRECTIONAL STIMULATION THERE ARE LESS NON-MOTOR SIDE EFFECTS THAT ARE SOMETIMES OBSERVED IN THESE PATIENTS IMPROVING THE QUALITY OF LIFE OF THE PATIENTS AND THE QUALITY OF THE ACTIVITIES THEY PERFORM.
- DIRECTIONAL STIMULATION OF THE SUBTHALAMIC NUCLEUS AND IMPULSE CONTROL DISORDER IN PARKINSON'S DISEASE.
- Protocol number: IMPULDIRECT
- Promoter: Clinica Universidad de Navarra
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.